| Identification | Back Directory | [Name]
CXCR7 modulator 2 | [CAS]
2227426-37-9 | [Synonyms]
CXCR7 modulator 2
CXCR-7 modulator 2,CXCR7 modulator 2
1H-1,4-Diazepine-1-propanamide, 4-(7-ethylimidazo[1,2-a]pyridin-8-yl)hexahydro-β-[1-[(1R,2S,4S)-7-oxabicyclo[2.2.1]hept-2-ylcarbonyl]-4-piperidinyl]-, (βS)- | [Molecular Formula]
C29H42N6O3 | [MOL File]
2227426-37-9.mol | [Molecular Weight]
522.69 |
| Hazard Information | Back Directory | [Uses]
CXCR7 modulator 2 is a modulator of C-X-C Chemokine Receptor Type 7 (CXCR7), with a Ki of 13 nM. | [in vivo]
The administration of isoproterenol for 9 days leads to the development of cardiac fibrosis, as attested by the approximately 4-fold increase in collagen deposition relative to that in the control, which is detected by picrosirius-red staining. Treatment with CXCR7 modulator 2 results in a statistically significant reduction in cardiac fibrosis, thereby demonstrating the protective role of CXCR7 modulation with CXCR7 modulator 2 in an isoproterenol-induced cardiac injury[1]. | [IC 50]
CXCR7: 13 nM (Ki) | [References]
[1] Menhaji-Klotz E, et al. Discovery of a Novel Small-Molecule Modulator of C-X-C Chemokine Receptor Type 7 as a Treatment for Cardiac Fibrosis. J Med Chem. 2018 Apr 26;61(8):3685-3696. DOI:10.1021/acs.jmedchem.8b00190 |
|
|